Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

NCT01797120 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Everolimus
DRUG: Placebo

Sponsor

PrECOG, LLC.

Collaborators

[object Object]